Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog - TheStreet

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

Third time was the charm for Alkermes' experimental antidepressant ALKS 5461.
10/20/16 4:06PM
Gilead is under enormous pressure from investors to acquire companies or develop new drugs from its pipeline.
10/20/16 12:24PM
Puma CEO Alan Auerbach wanted the cash desperately, regardless of Puma's stock price. Get the deal done, even if you have to sell it to the shorts.
10/20/16 8:40AM
Celgene is not some dinky micro-cap biotech lacking the resources or knowledge to conduct a rigorous clinical trial, so omitting a placebo arm from the GED-0301 study is inexcusable.
10/19/16 7:28AM
Why Trump is killing biotech stocks, the Shire-for-Radius rumor makes no sense and Bernie Sanders gets a tweeting lesson.
10/17/16 11:31AM
On Monday, PTC said the U.S. Food and Drug Administration denied an appeal of the Translarna refuse-to-file letter issued last February.
10/17/16 8:32AM
Investors had reduced expectations for Celgene's experimental pill for Crohn's disease, which makes the new clinical data released Sunday night look all right, although doubts will persist.
10/17/16 6:46AM
The biotech firm's stock sold off sharply during Friday's trading session -- one day after announcing improvements to its gene therapy for rare blood diseases.
10/14/16 5:27PM
Are the Baker Brothers selling Seattle Genetics? Biomarin CEO throws shade on Sarepta. TG Therapeutics management adds to its credibility problem.
10/13/16 11:39AM
Tesaro is soaring, but the company is overvalued if regulators decide to grant marketing clearance for niraparib only in a smaller, more restricted population of ovarian cancer patients.
10/10/16 1:22PM
Six of nine breast cancer patients treated with an experimental gene therapy from Ziopharm Oncology ZIOP experienced a potentially dangerous immune system-related toxicity known as cytokine release syndrome.
10/10/16 8:58AM
Merck's Keytruda works in first-line lung cancer, Bristol's Opdivo does not.
10/9/16 7:50AM
Tesaro expects to file a new drug application before the end of the year for niraparib as a maintenance therapy for ovarian cancer.
10/8/16 2:16AM
Takeover speculation that had fueled the recent rise in Clovis' stock price looks to be subsiding.
10/7/16 10:28AM
Ariad Pharmaceuticals' Iclusig now costs patients nearly $199,000 per year.
10/6/16 12:05PM
Alnylam said Wednesday evening that it was scrapping development of revusiran, one of the two most advanced gene-silencing drugs in the company's pipeline.
10/6/16 10:33AM
The FDA's pattern could be trouble for Dynavax' vaccine.
10/4/16 10:49AM
A cancer research meeting beginning on Friday will provide investors with an opportunity to inspect updated clinical data on two competing PARP inhibitors from Clovis Oncology and Tesaro.
10/4/16 7:35AM
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
9/30/16 7:00AM
The "placebo ate my clinical trial" excuse doesn't make sense, which places Intra-Cellular's plan to seek marketing approval for its schizophrenia drug in serious jeopardy.
9/29/16 5:52AM
A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.
9/27/16 7:00AM
Amgen's effort to improve disappointing sales of its multiple myeloma drug Kyprolis took a hit Tuesday with the failure of a phase III clinical trial involving newly diagnosed patients.
9/27/16 6:27AM
Kite Pharma's CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with an aggressive form of lymphoma, the company said Tuesday.
9/26/16 4:32PM
Failure is very profitable for Pain Therapeutics CEO Remi Barbier.
9/26/16 11:41AM